Back to results
Not yet recruitingPhase 4

Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer

NCT05841849

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

the Second Affiliated Hospital of Zhejiang Univercity School of Medicine

Hanzhou, Zhejiang, China

View on ClinicalTrials.gov
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer — TrialFind